Cargando…

Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience

There is currently no consensus on the most suitable therapeutic approach for psoriasis (PS) co-existing with posthepatic cirrhosis (PCs) and hepatocellular carcinoma (HCC) following liver transplantation (LT). The present study provides an analysis of the therapeutic experience of such patients. Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lin, Du, Guo-Sheng, Pan, Li-Chao, Zheng, Yong-Gen, Liu, Zhi-Jia, Shi, Hai-Da, Yang, Shao-Zhen, Shi, Xian-Jie, Xuan, Meng, Feng, Li-Kui, Zhu, Zhi-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755223/
https://www.ncbi.nlm.nih.gov/pubmed/29344227
http://dx.doi.org/10.3892/ol.2017.7217
_version_ 1783290558788141056
author Zhou, Lin
Du, Guo-Sheng
Pan, Li-Chao
Zheng, Yong-Gen
Liu, Zhi-Jia
Shi, Hai-Da
Yang, Shao-Zhen
Shi, Xian-Jie
Xuan, Meng
Feng, Li-Kui
Zhu, Zhi-Dong
author_facet Zhou, Lin
Du, Guo-Sheng
Pan, Li-Chao
Zheng, Yong-Gen
Liu, Zhi-Jia
Shi, Hai-Da
Yang, Shao-Zhen
Shi, Xian-Jie
Xuan, Meng
Feng, Li-Kui
Zhu, Zhi-Dong
author_sort Zhou, Lin
collection PubMed
description There is currently no consensus on the most suitable therapeutic approach for psoriasis (PS) co-existing with posthepatic cirrhosis (PCs) and hepatocellular carcinoma (HCC) following liver transplantation (LT). The present study provides an analysis of the therapeutic experience of such patients. Five LT recipients (two with PC and three with HCC) with accompanying PS were included. The induction program consisted of methylprednisolone plus basiliximab treatment. The initial postoperative treatment scheme consisted of tacrolimus (FK506) plus mycophenolate mofetil (MMF) and hormone; the latter was withdrawn 1 week after LT. The patients with PC had been using FK506 with or without a postoperative MMF program; the patients with HCC and recurrence of PS had been switched to a sirolimus (SRL)-based replacement therapy. Furthermore, all patients received anti-hepatitis B virus (HBV) therapy. The patients were followed up after 8.3±1.5 years. There was a positive correlation between HBV-DNA copy numbers, and psoriatic area and severity index (PASI) scores (r=0.97; P=0.006). The PASI scores were decreased significantly at 6 months following surgery compared with pre-transplantation (P<0.05). The patients who had received the FK506-based treatment experienced PS recurrence two years post-transplantation. The PASI scores increased significantly (P<0.05) and then declined gradually, maintaining a stable level (P<0.05) by 1 year after switching to the SRL-based treatment. The patients who had received the SRL-based treatment exhibited no recurrence of PS. The results of the present study suggest that SRL therapy provides a promising novel treatment method for patients with PS following LT that may be superior to tacrolimus treatment. When co-existing HBV is present pre-transplantation, regular injection of human hepatitis B immunoglobulin should be used to prevent the HBV from relapsing or aggravating the PS.
format Online
Article
Text
id pubmed-5755223
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-57552232018-01-17 Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience Zhou, Lin Du, Guo-Sheng Pan, Li-Chao Zheng, Yong-Gen Liu, Zhi-Jia Shi, Hai-Da Yang, Shao-Zhen Shi, Xian-Jie Xuan, Meng Feng, Li-Kui Zhu, Zhi-Dong Oncol Lett Articles There is currently no consensus on the most suitable therapeutic approach for psoriasis (PS) co-existing with posthepatic cirrhosis (PCs) and hepatocellular carcinoma (HCC) following liver transplantation (LT). The present study provides an analysis of the therapeutic experience of such patients. Five LT recipients (two with PC and three with HCC) with accompanying PS were included. The induction program consisted of methylprednisolone plus basiliximab treatment. The initial postoperative treatment scheme consisted of tacrolimus (FK506) plus mycophenolate mofetil (MMF) and hormone; the latter was withdrawn 1 week after LT. The patients with PC had been using FK506 with or without a postoperative MMF program; the patients with HCC and recurrence of PS had been switched to a sirolimus (SRL)-based replacement therapy. Furthermore, all patients received anti-hepatitis B virus (HBV) therapy. The patients were followed up after 8.3±1.5 years. There was a positive correlation between HBV-DNA copy numbers, and psoriatic area and severity index (PASI) scores (r=0.97; P=0.006). The PASI scores were decreased significantly at 6 months following surgery compared with pre-transplantation (P<0.05). The patients who had received the FK506-based treatment experienced PS recurrence two years post-transplantation. The PASI scores increased significantly (P<0.05) and then declined gradually, maintaining a stable level (P<0.05) by 1 year after switching to the SRL-based treatment. The patients who had received the SRL-based treatment exhibited no recurrence of PS. The results of the present study suggest that SRL therapy provides a promising novel treatment method for patients with PS following LT that may be superior to tacrolimus treatment. When co-existing HBV is present pre-transplantation, regular injection of human hepatitis B immunoglobulin should be used to prevent the HBV from relapsing or aggravating the PS. D.A. Spandidos 2017-12 2017-10-18 /pmc/articles/PMC5755223/ /pubmed/29344227 http://dx.doi.org/10.3892/ol.2017.7217 Text en Copyright: © Zhou et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhou, Lin
Du, Guo-Sheng
Pan, Li-Chao
Zheng, Yong-Gen
Liu, Zhi-Jia
Shi, Hai-Da
Yang, Shao-Zhen
Shi, Xian-Jie
Xuan, Meng
Feng, Li-Kui
Zhu, Zhi-Dong
Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience
title Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience
title_full Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience
title_fullStr Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience
title_full_unstemmed Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience
title_short Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience
title_sort sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: a single center experience
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755223/
https://www.ncbi.nlm.nih.gov/pubmed/29344227
http://dx.doi.org/10.3892/ol.2017.7217
work_keys_str_mv AT zhoulin sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT duguosheng sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT panlichao sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT zhengyonggen sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT liuzhijia sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT shihaida sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT yangshaozhen sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT shixianjie sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT xuanmeng sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT fenglikui sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience
AT zhuzhidong sirolimustreatmentforcirrhosisorhepatocellularcarcinomapatientsaccompaniedbypsoriasisafterlivertransplantationasinglecenterexperience